title: Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.
abstract: Sexual dysfunction (SD) is a common and underestimated effect of antidepressants. Healthy volunteers are the most adequate group to study this adverse event avoiding influence of depression itself. Sexual acceptability of agomelatine (a melatonergic agonist and 5HT(2C) antagonist) paroxetine and placebo by using the Psychotropic-Related Sexual Dysfunction Salamanca Sex Questionnaire (PRSEXDQ-SALSEX) was explored. A total of 92 healthy male volunteers were randomised to agomelatine (25 or 50 mg), paroxetine 20 mg or placebo for 8 weeks. SD, defined as at least one sexual impairment in one of the following PRSEXDQ-SALSEX items (decreased libido, delayed orgasm/ejaculation, anorgasmia/no ejaculation and erectile dysfunction), was evaluated at baseline and after 2, 4 and 8 weeks. At the last post-baseline assessment, SD was significantly lower in each agomelatine group (22.7% on 25 mg and 4.8% on 50 mg) than in the paroxetine group (85.7%; p < 0.0001). In the placebo group, 8.7% of volunteers reported a SD. The percentages of volunteers with moderate or severe SD were 4.5% for agomelatine 25 mg, 4.8% for agomelatine 50 mg, 61.9% for paroxetine 20 mg and 0% in the placebo group (p < or = 0.0001 agomelatine versus paroxetine). There is a much lower risk of having SD with agomelatine than paroxetine in healthy male volunteers, which confirms the better sexual acceptability profile of agomelatine compared with the SSRIs.
authors.affiliation: Servicio de Psiquiatría, Hospital Universitario de Salamanca, Salamanca, Spain. amontejo@usal.es
authors.forename: A L
authors.initials: AL
authors.lastname: Montejo
authors.forename: N
authors.initials: N
authors.lastname: Prieto
authors.forename: A
authors.initials: A
authors.lastname: Terleira
authors.forename: J
authors.initials: J
authors.lastname: Matias
authors.forename: S
authors.initials: S
authors.lastname: Alonso
authors.forename: G
authors.initials: G
authors.lastname: Paniagua
authors.forename: S
authors.initials: S
authors.lastname: Naval
authors.forename: D G
authors.initials: DG
authors.lastname: Parra
authors.forename: C
authors.initials: C
authors.lastname: Gabriel
authors.forename: E
authors.initials: E
authors.lastname: Mocaër
authors.forename: A
authors.initials: A
authors.lastname: Portolés
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D017374:Paroxetine / Q000009:adverse effects*; D011594:Psychometrics; D012720:Severity of Illness Index; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced*; D011795:Surveys and Questionnaires; D013997:Time Factors; D055815:Young Adult; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D018687:Antidepressive Agents, Second-Generation; D006993:Hypnotics and Sedatives; D017374:Paroxetine; C084711:agomelatine; D009281:Naphthalenes